A5085988624- Blood Coagulation and Thrombosis Mechanisms
- Venous Thromboembolism Diagnosis and Management
- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Systemic Lupus Erythematosus Research
- Cardiovascular Issues in Pregnancy
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Heparin-Induced Thrombocytopenia and Thrombosis
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Pregnancy and preeclampsia studies
- Eosinophilic Disorders and Syndromes
- Atrial Fibrillation Management and Outcomes
- Complement system in diseases
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Lymphoma Diagnosis and Treatment
- Blood disorders and treatments
- Central Venous Catheters and Hemodialysis
- Lysosomal Storage Disorders Research
- Retinoids in leukemia and cellular processes
- Kruppel-like factors research
- Growth Hormone and Insulin-like Growth Factors
- Hemostasis and retained surgical items
- Cancer-related gene regulation
University of Belgrade
2015-2024
Univerzitetski Klinički Centar Srbije
2004-2024
Centar za Promociju Nauke
2005-2020
Institute for Pulmonary Diseases of Vojvodina
2009
University Clinical Centre
2000-2006
Severe congenital protein C deficiency (SCPCD) is rare and there currently substantial variation in the management of this condition. A joint project by three Scientific Standardization Committees ISTH: Plasma Coagulation Inhibitors, Pediatric/Neonatal Thrombosis Hemostasis, Women's Health Issues was developed to review current evidence help guide on diagnosis SCPCD. We provide a summary clinical presentations, differential diagnoses, appropriate investigations confirm diagnosis, approaches...
Research Articles| November 25 2004 Prevalence of Factor V Leiden, Cambridge, II G20210A and Methylenetetrahydrofolate Reductase C677T Mutations in Healthy Thrombophilic Serbian Populations Subject Area: Hematology , Oncology V. Djordjevic; Djordjevic Institute Molecular Genetics Genetic Engineering, Search for other works by this author on: This Site PubMed Google Scholar L.J. Rakicevic; Rakicevic D. Mikovic; Mikovic Hemostasis Department Hemophilia Center, National Blood Transfusion...
Abstract Introduction Turoctocog alfa is a recombinant factor VIII (FVIII) molecule, approved for treatment and prophylaxis of bleeding in patients with haemophilia A. In the guardian 1 (adolescents/adults) 3 (children) phase trials, turoctocog demonstrated favourable efficacy safety profile. Guardian or completers could enrol 2 extension. Final results are reported here. Aim Investigate long‐term administered bleeds. Methods this 3b open‐label trial, previously treated males all ages severe...
Abstract Background Factor VIII (FVIII) products are usually dosed according to body weight (BW). This may lead under- or over-dosing in underweight obese patients, respectively. Objective article evaluates the pharmacokinetics (PK) of recombinant FVIII concentrate, particularly recovery, relation mass index (BMI) and other composition descriptors. Materials Methods Thirty-five previously treated adults with severe haemophilia A from five BMI categories (underweight, normal, overweight,...
There is a paucity of data on the effects enzyme replacement therapy (ERT) coagulation abnormalities and platelet function patients with Gaucher's disease (GDPs) much this are controversial. This study investigates haemostatic parameters in treatment-naïve GDPs ERT. 31 Serbian type 1 (M/F 17/14; median age 49 years, splenectomized 9/31) were studied. The complete blood count, prothrombin time (PT), activated partial tromboplastin (aPTT) factors measured using standard methods. Platelet...
Thrombosis is a major global disease burden with almost 60% of cases related to underlying heredity and most still idiopathic. Synonymous single nucleotide polymorphisms (sSNPs) are considered silent phenotypically neutral. Our previous study revealed novel synonymous FII c.1824C>T variant as potential risk factor for pregnancy loss, but it has not yet been associated thrombotic diseases.To determine the frequency we have sequenced patients' DNA. Prothrombin RNA expression was measured by...
Background. Venous thrombosis is the most common cause of obstetric morbidity and mortality during pregnancy puerperium. The incidence associated venous varies from 1 in 1000 to 2000 deliveries. Factor V G1691A (FV Leiden), FII G20210A MTHFR C677T mutations are genetic risk factors for thromboembolism. aim this study was establish presence these a group women with an episode deep or Methods. carried 45 first patients antiphospholipid antibodies, antithrombin III, protein C S deficiency,...